CYFRA21-1、SCCA及NSE在卵巢癌辅助诊断及预后评估中的作用

The role of CYFRA21⁃1,SCCA and NSE in the auxiliary diagnosis and prognosis of ovarian cancer

目的分析细胞角蛋白19片段(CYFRA21-1)、鳞状细胞癌抗原(SCCA)及神经元特异性烯醇化酶(NSE)在卵巢癌辅助诊断及预后评估中的作用。方法选取2020年12月至2022年7月于沧州市中心医院进行治疗的卵巢癌患者131例为研究对象(观察组),另选取80名同期院内健康体检者作为对照组。对比两组血清CYFRA21-1、SCCA、NSE水平;对比观察组Ⅰ~Ⅱ期、Ⅲ~Ⅳ期的血清CYFRA21-1、SCCA、NSE水平;绘制ROC曲线,分析血清CYFRA21-1、SCCA、NSE单独检测及联合检测卵巢癌的价值;采用logistic回归分析影响卵巢癌预后的单因素、多因素。结果血清CYFRA21-1、SCCA、NSE:观察组治疗前>观察组治疗后>对照组,差异具有统计学意义(P<0.05);Ⅲ~Ⅳ期患者的血清CYFRA21-1、SCCA、NSE水平均高于Ⅰ~Ⅱ期,差异具有统计学意义(P<0.05);CYFRA21-1+SCCA+NSE联合诊断卵巢癌的AUC为0.851,高于三指标单独检测(P<0.05);经随访,52例患者预后不良,79例患者预后良好;经过logistic多因素分析显示,临床分期为Ⅲ~Ⅳ期、CYFRA21-1>2.08 ng/mL、SCCA>1.50μg/mL、NSE>12.50 ng/mL是影响卵巢癌预后的独立危险因素(P<0.05)。结论卵巢癌患者接受血清CYFRA21-1、SCCA、NSE辅助诊断,可有效提高疾病诊断价值,预测疾病进展。

Objective To analyze (CYFRA21⁃1,SCCA)and NSE in adjuvant diagnosis and prog⁃nosis assessment of ovarian cancer.Methods 131 patients with ovarian cancer who were treated at our hospi⁃tal from December 2020 to July 2022 were selected as the study subjects(observation group).Another 80 healthy patients who underwent physical examinations at our hospital during the same period were selected as the normal control group.Serum levels of CYFRA21⁃1,SCCA and NSE were also compared between the two groups.The serum levels of CYFRA21⁃1,SCCA and NSE in the observation group were compared in stagesⅠtoⅡandⅢtoⅣ.ROC curves were drawn to analyze the value of serum CYFRA21⁃1,SCCA,NSE alone,and combined detection for ovarian cancer.Logistic regression was used to analyze the single and multiple fac⁃tors affecting the prognosis of ovarian cancer.Results Serum levels of CYFRA21⁃1,SCCA,and NSE:the observation group before treatment>the observation group after treatment>the control group,the difference was statistically significant(P<0.05).The levels of CYFRA21⁃1,SCCA and NSE in the serum of patients in stagesⅢ~Ⅳwere higher than those in stagesⅠ~Ⅱ(P<0.05).The AUC of CYFRA21⁃1+SCCA+NSE in the diagnosis of ovarian cancer was 0.851,which was higher than that of CYFRA21⁃1,SCCA and NSE alone(P<0.05).After follow⁃up,52 patients had a poor prognosis,and 79 patients had a good prognosis.Logistic multivariate analysis showed that clinical stagesⅢ~Ⅳ,CYFRA21⁃1>2.08 ng/mL,SCCA>1.50μg/mL,NSE>12.50 ng/mL were independent risk factors for ovarian cancer prognosis(P<0.05).Conclusion Ovarian cancer patients who underwent serum tests for CYFRA21⁃1,SCCA,and NSE can effectively enhance the accuracy of diagnosis and offer valuable insights for predicting patient prognosis in clinical settings.